187 related articles for article (PubMed ID: 35910796)
41. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
Anderson MA; Deng J; Seymour JF; Tam C; Kim SY; Fein J; Yu L; Brown JR; Westerman D; Si EG; Majewski IJ; Segal D; Heitner Enschede SL; Huang DC; Davids MS; Letai A; Roberts AW
Blood; 2016 Jun; 127(25):3215-24. PubMed ID: 27069256
[TBL] [Abstract][Full Text] [Related]
42. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
Dasmahapatra G; Lembersky D; Son MP; Patel H; Peterson D; Attkisson E; Fisher RI; Friedberg JW; Dent P; Grant S
Mol Cancer Ther; 2012 May; 11(5):1122-32. PubMed ID: 22411899
[TBL] [Abstract][Full Text] [Related]
43. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
[TBL] [Abstract][Full Text] [Related]
44. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
45. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
[TBL] [Abstract][Full Text] [Related]
46. Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax.
Herzog LO; Walters B; Buono R; Lee JS; Mallya S; Fung A; Chiu H; Nguyen N; Li B; Pinkerton AB; Jackson MR; Schneider RJ; Ronai ZA; Fruman DA
Br J Cancer; 2021 Mar; 124(6):1098-1109. PubMed ID: 33318657
[TBL] [Abstract][Full Text] [Related]
47. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.
Khaw SL; Suryani S; Evans K; Richmond J; Robbins A; Kurmasheva RT; Billups CA; Erickson SW; Guo Y; Houghton PJ; Smith MA; Carol H; Roberts AW; Huang DC; Lock RB
Blood; 2016 Sep; 128(10):1382-95. PubMed ID: 27343252
[TBL] [Abstract][Full Text] [Related]
48. Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma.
Bogusz AM; Baxter RH; Currie T; Sinha P; Sohani AR; Kutok JL; Rodig SJ
Clin Cancer Res; 2012 Nov; 18(22):6122-35. PubMed ID: 22966017
[TBL] [Abstract][Full Text] [Related]
49. CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues.
Yu X; Munoz-Sagredo L; Streule K; Muschong P; Bayer E; Walter RJ; Gutjahr JC; Greil R; Concha ML; Müller-Tidow C; Hartmann TN; Orian-Rousseau V
Blood; 2021 Sep; 138(12):1067-1080. PubMed ID: 34115113
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic synergy between tigecycline and venetoclax in a preclinical model of
Ravà M; D'Andrea A; Nicoli P; Gritti I; Donati G; Doni M; Giorgio M; Olivero D; Amati B
Sci Transl Med; 2018 Jan; 10(426):. PubMed ID: 29386360
[TBL] [Abstract][Full Text] [Related]
51. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
52. High
Salwa A; Ferraresi A; Secomandi E; Vallino L; Moia R; Patriarca A; Garavaglia B; Gaidano G; Isidoro C
Cells; 2023 Jul; 12(15):. PubMed ID: 37566004
[TBL] [Abstract][Full Text] [Related]
53. The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.
Nguyen LXT; Troadec E; Kalvala A; Kumar B; Hoang DH; Viola D; Zhang B; Nguyen DQ; Aldoss I; Ghoda L; Budde E; Pichiorri F; Rosen S; Forman SJ; Marcucci G; Pullarkat V
J Cell Physiol; 2019 Aug; 234(8):14040-14049. PubMed ID: 30623427
[TBL] [Abstract][Full Text] [Related]
54. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
[TBL] [Abstract][Full Text] [Related]
55. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.
Fiskus W; Mill CP; Perera D; Birdwell C; Deng Q; Yang H; Lara BH; Jain N; Burger J; Ferrajoli A; Davis JA; Saenz DT; Jin W; Coarfa C; Crews CM; Green MR; Khoury JD; Bhalla KN
Leukemia; 2021 Sep; 35(9):2621-2634. PubMed ID: 33654205
[TBL] [Abstract][Full Text] [Related]
56. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
[TBL] [Abstract][Full Text] [Related]
57. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
[TBL] [Abstract][Full Text] [Related]
58. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
[TBL] [Abstract][Full Text] [Related]
59. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition.
Carter BZ; Mak PY; Tao W; Warmoes M; Lorenzi PL; Mak D; Ruvolo V; Tan L; Cidado J; Drew L; Andreeff M
Haematologica; 2022 Jan; 107(1):58-76. PubMed ID: 33353284
[TBL] [Abstract][Full Text] [Related]
60. BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression.
Cummin TEC; Cox KL; Murray TD; Turaj AH; Dunning L; English VL; Fell R; Packham G; Ma Y; Powell B; Johnson PWM; Cragg MS; Carter MJ
Blood Adv; 2020 Jul; 4(14):3316-3328. PubMed ID: 32717030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
